Table 4.
Adherence and persistence by oral anticoagulant
| Overall | VKA | Dabigatran | Rivaroxaban | Apixaban | |
| Total, n (%) | 36 652 | 25 008 | 1285 | 5855 | 4504 |
| Zero follow-up | 16 (0.04) | 7 (0.03) | 1 (0.08) | 5 (0.09) | 3 (0.07) |
| Total <1 year of data | 11 373 (31.0) | 5307 (21.2) | 441 (34.3) | 3014 (51.5) | 2611 (58.0) |
| Primary non-adherence | 1800 (15.8) | 818 (15.4) | 78 (17) | 531 (17.6) | 373 (14.3) |
| Non-adherent | 3178 (27.9) | 1654 (31.2) | 94 (21.3) | 771 (25.6) | 659 (25.2) |
| Adherent | 6395 (56.2) | 2835 (53.4) | 269 (61.0) | 1712 (56.8) | 1579 (60.5) |
| Total ≥1 year of data | 25 263 (68.9) | 19 694 (78.8) | 843 (65.6) | 2836 (48.4) | 1890 (42.0) |
| Primary non-adherence | 876 (3.5) | 631 (3.2) | 66 (7.8) | 128 (4.5) | 51 (2.7) |
| Non-adherent, non-persistent | 5352 (21.2) | 4616 (23.4) | 124 (14.7) | 378 (13.3) | 234 (12.4) |
| Adherent, non-persistent | 2173 (8.6) | 1711 (8.7) | 132 (15.7) | 232 (8.2) | 98 (5.2) |
| Non-adherent, persistent | 6699 (26.5) | 5221 (26.5) | 164 (19.5) | 766 (27.0) | 548 (29.0) |
| Persistent, adherent | 10 163 (40.2) | 7515 (38.2) | 357 (42.3) | 1332 (47.0) | 959 (50.7) |
VKA, vitamin K antagonist.